Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
New funding will expand CytoReason's disease models and proprietary data, enabling R&D leaders at partner companies to make strategic decisions with greater speed and precision.
CytoReason, a leader in developing computational disease models for predictive insights, announced today it secured an aggregated $80 million from OurCrowd, NVIDIA (NASDAQ:NVDA), Pfizer (NYSE:PFE), and Thermo Fisher Scientific (NYSE:TMO).
CytoReason will use this investment to expand the application of its models into additional indications, grow its proprietary molecular and clinical data, and establish an office in Cambridge, Massachusetts later this year.
Reduced R&D timelines and improved probability of technical and regulatory success (PTRS) are top priorities across life sciences companies. Speed, safety, and accuracy are critical when making asset-related R&D decisions. CytoReason provides therapeutic area leaders with molecular-level insights and valuable AI tools to make data-driven decisions, helping them improve the probability of phase 2 success and optimize their R&D portfolio.